These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34133089)

  • 61. Vortioxetine vs. Other Antidepressants in Patients with Major Depressive Episode With or Without Substance Use Disorder.
    Kotzalidis GD; Lombardozzi G; Matrone M; Amici E; Perrini F; Cuomo I; De Filippis S
    Curr Neuropharmacol; 2021; 19(12):2296-2307. PubMed ID: 33441069
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Therapeutic Potential of Vortioxetine for Anxious Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan.
    Inoue T; Fujimoto S; Marumoto T; Kitagawa T; Ishida K; Nakajima T; Moriguchi Y; Fujikawa K; Watanabe K
    Neuropsychiatr Dis Treat; 2021; 17():3781-3790. PubMed ID: 34992372
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.
    Papakostas GI; Salloum NC; Hock RS; Jha MK; Murrough JW; Mathew SJ; Iosifescu DV; Fava M
    J Clin Psychiatry; 2020 May; 81(4):. PubMed ID: 32459407
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Tran P; Skolnick P; Czobor P; Huang NY; Bradshaw M; McKinney A; Fava M
    J Psychiatr Res; 2012 Jan; 46(1):64-71. PubMed ID: 21925682
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inflammation-stratified augmentation of vortioxetine with celecoxib: Results from a double-blind, randomized, placebo-controlled trial in major depressive disorder.
    Kavakbasi E; Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert KO; Clark SR; Fourrier C; Baune BT
    J Neurochem; 2024 Sep; 168(9):1817-1825. PubMed ID: 37635396
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.
    Trivedi MH; Corey-Lisle PK; Guo Z; Lennox RD; Pikalov A; Kim E
    Int Clin Psychopharmacol; 2009 May; 24(3):133-8. PubMed ID: 19318972
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling.
    Zimmerman M; Clark HL; Multach MD; Walsh E; Rosenstein LK; Gazarian D
    J Affect Disord; 2016 Jan; 190():357-361. PubMed ID: 26546771
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes.
    Di Nicola M; Pepe M; Montanari S; Spera MC; Panaccione I; Simonetti A; Sani G
    Eur Neuropsychopharmacol; 2023 May; 70():21-28. PubMed ID: 36808043
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Differential Response to Three Antidepressants in Patients with Major Depressive Episode Who Suffered Covid-19-Related Trauma.
    De Filippis S; Lombardozzi G; Matrone M; Amici E; Trovini G; Perrini F; Di Giovanni A; Giovanetti V; Kotzalidis GD
    Curr Neuropharmacol; 2022 Nov; 20(12):2393-2407. PubMed ID: 35272591
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder.
    Baune BT; Brignone M; Larsen KG
    Int J Neuropsychopharmacol; 2018 Feb; 21(2):97-107. PubMed ID: 29053849
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
    Vieta E; Sluth LB; Olsen CK
    J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: The MEMORY study.
    Christensen MC; Schmidt SN; Grande I
    J Affect Disord; 2023 Oct; 338():423-431. PubMed ID: 37315590
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine.
    Subramaniapillai M; Mansur RB; Zuckerman H; Park C; Lee Y; Iacobucci M; Cao B; Ho R; Lin K; Phan L; McIntyre RS
    Compr Psychiatry; 2019 Oct; 94():152113. PubMed ID: 31404802
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.
    Fagiolini A; Florea I; Loft H; Christensen MC
    J Affect Disord; 2021 Mar; 283():472-479. PubMed ID: 33516560
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis.
    Hock RS; Feeney A; Iovieno N; Murrough JW; Mathew SJ; Iosifescu DV; Fava M; Jha MK; Papakostas GI
    J Clin Psychiatry; 2022 Dec; 84(1):. PubMed ID: 36516320
    [No Abstract]   [Full Text] [Related]  

  • 80. Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo.
    Kornstein SG; Fava M; Jiang Q; Tourian KA
    Psychopharmacol Bull; 2009; 42(3):21-35. PubMed ID: 19752839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.